A Randomized, Single-blind, Two-period Crossover to Investigate the Effect of SEP-363856 on the Pharmacokinetics of Metformin in Subjects With Schizophrenia
Latest Information Update: 09 Jul 2024
At a glance
- Drugs Ulotaront (Primary) ; Metformin
- Indications Schizophrenia
- Focus Pharmacokinetics
- Sponsors Otsuka Pharmaceutical Development & Commercialization; Sumitomo Pharma America
- 31 May 2022 Status changed from active, no longer recruiting to completed.
- 06 Apr 2022 Planned End Date changed from 31 Mar 2022 to 30 Apr 2022.
- 06 Apr 2022 Planned primary completion date changed from 31 Mar 2022 to 30 Apr 2022.